JP2015518056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518056A5 JP2015518056A5 JP2015515272A JP2015515272A JP2015518056A5 JP 2015518056 A5 JP2015518056 A5 JP 2015518056A5 JP 2015515272 A JP2015515272 A JP 2015515272A JP 2015515272 A JP2015515272 A JP 2015515272A JP 2015518056 A5 JP2015518056 A5 JP 2015518056A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- coq10
- coq10 compound
- dose
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 85
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 85
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 85
- -1 CoQ10 compound Chemical class 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 29
- 238000009104 chemotherapy regimen Methods 0.000 claims description 21
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical class COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 15
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000014207 opsonization Effects 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010070308 Refractory cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229940020967 gemzar Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 150000003058 platinum compounds Chemical class 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
- 201000000270 spindle cell sarcoma Diseases 0.000 claims description 2
- 210000002437 synoviocyte Anatomy 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 208000019983 tonsillar squamous cell carcinoma Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 241000321096 Adenoides Species 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- 201000007180 bile duct carcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 67
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 5
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654245P | 2012-06-01 | 2012-06-01 | |
| US61/654,245 | 2012-06-01 | ||
| PCT/US2013/043785 WO2013181639A1 (en) | 2012-06-01 | 2013-05-31 | Treatment of solid tumors using coenzyme q10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109093A Division JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518056A JP2015518056A (ja) | 2015-06-25 |
| JP2015518056A5 true JP2015518056A5 (enExample) | 2016-07-21 |
| JP6352905B2 JP6352905B2 (ja) | 2018-07-04 |
Family
ID=49673946
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515272A Active JP6352905B2 (ja) | 2012-06-01 | 2013-05-31 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2018109093A Withdrawn JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2020127877A Active JP7225167B2 (ja) | 2012-06-01 | 2020-07-29 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109093A Withdrawn JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2020127877A Active JP7225167B2 (ja) | 2012-06-01 | 2020-07-29 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140017317A1 (enExample) |
| EP (1) | EP2854528B8 (enExample) |
| JP (3) | JP6352905B2 (enExample) |
| KR (2) | KR20200118233A (enExample) |
| CN (1) | CN104507308A (enExample) |
| AU (2) | AU2013267166A1 (enExample) |
| BR (1) | BR112014029954A2 (enExample) |
| CA (2) | CA2875150C (enExample) |
| EA (1) | EA032345B1 (enExample) |
| ES (1) | ES2761449T3 (enExample) |
| IL (1) | IL236008B (enExample) |
| IN (1) | IN2014DN10734A (enExample) |
| MX (2) | MX369768B (enExample) |
| NZ (1) | NZ702369A (enExample) |
| SG (1) | SG11201407880QA (enExample) |
| WO (1) | WO2013181639A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2429511B1 (en) | 2009-05-11 | 2019-02-20 | Berg LLC | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
| NZ702369A (en) * | 2012-06-01 | 2016-12-23 | Berg Llc | Treatment of solid tumors using coenzyme q10 |
| US10933032B2 (en) * | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
| CN121197124A (zh) | 2013-09-04 | 2025-12-26 | 博格有限责任公司 | 通过持续输注辅酶q10来治疗癌症的方法 |
| US9996463B2 (en) * | 2015-11-10 | 2018-06-12 | International Business Machines Corporation | Selection and placement of volumes in a storage system using stripes |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20170255565A1 (en) * | 2016-03-02 | 2017-09-07 | Intel Corporation | Method and apparatus for providing a contiguously addressable memory region by remapping an address space |
| WO2018005412A1 (en) * | 2016-06-28 | 2018-01-04 | Tien Yang Der | Chemoprotective/chemoactive nanodroplets and methods of use thereof |
| CA3063916A1 (en) * | 2017-05-17 | 2018-11-22 | Berg Llc | Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa |
| AU2022400186A1 (en) * | 2021-12-01 | 2024-06-20 | Gambro Lundia Ab | New dialysis fluid |
| WO2025087731A1 (en) * | 2023-10-24 | 2025-05-01 | Gambro Lundia Ab | Compositions comprising insulin and ketones bodies to treat cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| WO2005048925A2 (en) * | 2003-11-14 | 2005-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| EP2371363B1 (en) * | 2004-01-22 | 2020-04-08 | University of Miami | Coenzyme Q10 formulations for use in the treatment of solid tumours |
| WO2008069276A1 (ja) * | 2006-12-06 | 2008-06-12 | Kaneka Corporation | 癌治療剤および発癌抑制剤 |
| US8454945B2 (en) | 2007-03-22 | 2013-06-04 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
| AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| EP2429511B1 (en) | 2009-05-11 | 2019-02-20 | Berg LLC | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| GB0913193D0 (en) | 2009-07-29 | 2009-09-02 | Johnson Matthey Plc | Deoxygenation process |
| EP3366280A1 (en) * | 2010-03-12 | 2018-08-29 | Berg LLC | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| MX369543B (es) | 2011-06-17 | 2019-11-12 | Berg Llc | Composiciones farmaceuticas inhalables. |
| NZ702369A (en) * | 2012-06-01 | 2016-12-23 | Berg Llc | Treatment of solid tumors using coenzyme q10 |
-
2013
- 2013-05-31 NZ NZ702369A patent/NZ702369A/en not_active IP Right Cessation
- 2013-05-31 CA CA2875150A patent/CA2875150C/en active Active
- 2013-05-31 MX MX2014014492A patent/MX369768B/es active IP Right Grant
- 2013-05-31 EA EA201492187A patent/EA032345B1/ru not_active IP Right Cessation
- 2013-05-31 KR KR1020207028370A patent/KR20200118233A/ko not_active Ceased
- 2013-05-31 AU AU2013267166A patent/AU2013267166A1/en not_active Abandoned
- 2013-05-31 IN IN10734DEN2014 patent/IN2014DN10734A/en unknown
- 2013-05-31 WO PCT/US2013/043785 patent/WO2013181639A1/en not_active Ceased
- 2013-05-31 BR BR112014029954A patent/BR112014029954A2/pt not_active IP Right Cessation
- 2013-05-31 ES ES13797642T patent/ES2761449T3/es active Active
- 2013-05-31 JP JP2015515272A patent/JP6352905B2/ja active Active
- 2013-05-31 EP EP13797642.9A patent/EP2854528B8/en active Active
- 2013-05-31 CN CN201380040105.3A patent/CN104507308A/zh active Pending
- 2013-05-31 US US13/907,726 patent/US20140017317A1/en not_active Abandoned
- 2013-05-31 CA CA3090268A patent/CA3090268A1/en not_active Abandoned
- 2013-05-31 SG SG11201407880QA patent/SG11201407880QA/en unknown
- 2013-05-31 KR KR1020147037100A patent/KR102163948B1/ko active Active
-
2014
- 2014-11-27 MX MX2019013776A patent/MX2019013776A/es unknown
- 2014-11-30 IL IL236008A patent/IL236008B/en active IP Right Grant
-
2016
- 2016-10-10 US US15/289,770 patent/US20170216223A1/en not_active Abandoned
-
2017
- 2017-04-19 AU AU2017202567A patent/AU2017202567B2/en not_active Ceased
-
2018
- 2018-06-07 JP JP2018109093A patent/JP2018168164A/ja not_active Withdrawn
-
2020
- 2020-07-29 JP JP2020127877A patent/JP7225167B2/ja active Active
-
2021
- 2021-05-17 US US17/321,699 patent/US20220096399A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518056A5 (enExample) | ||
| Saghatelyan et al. | Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial | |
| JP2020183440A5 (enExample) | ||
| Carlson et al. | Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity | |
| US10016365B2 (en) | Compositions and methods of tumor treatment utilizing nanoparticles | |
| CN104245699B (zh) | Nedd8‑活化酶抑制剂和低甲基化剂的投与 | |
| Löhr et al. | A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer | |
| EP2424516A2 (en) | Pentamidine combinations for treating cancer | |
| Berk et al. | XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer | |
| JP2018517759A5 (enExample) | ||
| KR20110025172A (ko) | 약제학적 병용물 | |
| Gatzemeier et al. | Tirapazamine-cisplatin: the synergy | |
| Laudani et al. | Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma | |
| AU2015317856B2 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| TW201821107A (zh) | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 | |
| Li et al. | Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer | |
| Kim et al. | Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer | |
| HK1223018A1 (zh) | 类胡萝卜素的医药组合物 | |
| CN102018670A (zh) | 一种抗癌制剂及其制备方法 | |
| WO2019113461A1 (en) | Lipid emulsified drug delivery systems for chemoprevention and treatment | |
| Messersmith et al. | 588 A first-in-patient phase I study of the novel gamma secretase inhibitor PF-03084014 in patients with advanced solid tumor malignancies | |
| CN102309491B (zh) | 一种替加氟、吉美斯特复方注射液 | |
| Farooqi et al. | Tumor lysis syndrome in metastatic colon cancer following treatment with regorafenib | |
| Schwartz et al. | The addition of chloroquine and metformine to Metabloc induces a rapid drop of tumor markers in advanced carcinoma | |
| Heudel et al. | Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial |